Prostate Cancer Clinical Trial
PSMA PET Imaging of Recurrent Prostate Cancer
The purpose of this study is to see if a new diagnostic research agent named 68Ga-HBED-CC-PSMA can show prostate cancer on a PET/CT scan that cannot be seen on other standard imaging even when the PSA levels are very low.
Biopsy proven adenocarcinoma of the prostate
Initially treated with definitive local therapy (surgery and radiation therapy are the most common treatments, but other treatments are also eligible)
For patients initially treated with surgery, radiation therapy, brachytherapy, or cryotherapy:
PSA ≥ 0.2 ng/mL in at least two consecutive tests within 6 months of date of consent for patients
Note: The most recent PSA value must be within 6 weeks of consent
For patients who have received additional treatment in the recurrent or metastatic setting:
° PSA ≥ 2 ng/ml above the most recent therapy nadir
Age ≥ 18 years
Patient must be able to tolerate PET/CT or PET/MR imaging
Patient with claustrophobia that would preclude PET/CT or PET/MR imaging or other contraindications to CT imaging.
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 7 Locations for this study
Basking Ridge New Jersey, 07920, United States
Middletown New Jersey, 07748, United States
Montvale New Jersey, 07645, United States
Commack New York, 11725, United States
Harrison New York, 10604, United States
New York New York, 10065, United States
Uniondale New York, 11553, United States
How clear is this clinincal trial information?
Introducing, the Journey Bar
Use this bar to access information about the steps in your cancer journey.